soul trial oral semaglutide cardiovascular outcomes 2024 2025 results (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Targeting the weight within: obesity
Pay in 4 interest-free payments of $5.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




:max_bytes(150000):strip_icc()/VWH-GettyImages-2158519129-372ed708fbbb4c6e9f472a8218cd52ee.jpg)




















